What is DermaSensor?
DermaSensor operates at the intersection of medical technology and artificial intelligence, specializing in non-invasive skin cancer detection. The company's flagship device provides healthcare professionals—ranging from family medicine practitioners to aesthetic specialists—with the clinical confidence required to assess suspicious lesions with high precision. By streamlining the diagnostic workflow, DermaSensor not only enhances patient outcomes through early detection but also optimizes the efficiency of medical practices. Its market position is defined by its commitment to evidence-based innovation, ensuring that primary care providers can perform accurate screenings without the immediate need for invasive procedures.
How much funding has DermaSensor raised?
DermaSensor has raised a total of $16M across 1 funding round:
Series B
$16M
Series B (2025): $16M with participation from Kern Venture Group, Pier 70 Ventures, and GenHenn Capital
Key Investors in DermaSensor
Kern Venture Group
Kern Venture Group is a venture capital firm based in the Central Valley of California that focuses on bridging gaps and fostering innovation, particularly in early-stage to Series B investments.
Pier 70 Ventures
Pier 70 Ventures invests in impact-driven technologies, particularly in healthcare, providing capital and mentorship to accelerate high-growth sustainable companies.
GenHenn Capital
GenHenn Capital is a venture capital firm focused on investing in early-stage life sciences, healthcare, and biotech companies that are developing high-impact solutions.
What's next for DermaSensor?
Looking ahead, the recent capital influx will likely be deployed to accelerate the commercial rollout of DermaSensor's diagnostic platform across diverse clinical settings. The company is well-positioned to expand its footprint in the healthcare sector, focusing on increasing adoption rates among primary care physicians and internal medicine practices. Strategic priorities will likely include further clinical validation studies, potential expansion into international markets, and the continuous refinement of its AI diagnostic models. As the firm transitions into this growth phase, the focus remains on maintaining high diagnostic standards while scaling the infrastructure necessary to support a broader user base of healthcare professionals.
See full DermaSensor company page
